… group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95… heart
failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (…

… Definite or probable ketoacidosis occurred in 2 patients without heart failure randomly
allocated to placebo; there were no cases of ketoacidosis in the dapagliflozin group. …

… safety of dapagliflozin for the management of chronic heart failure. We showed that dapagliflozin
can … death/hospitalization for heart failure, cardiovascular death, and hospitalization for …

… Dapagliflozin in patients with heart failure and reduced … Failure (DAPA-HF) trial included
patients with heart failure and … Dapagliflozin reduced the risk of worsening heart failure events …

… or worsening heart failure when dapagliflozin was initiated in patients with heart failure with
… large absolute risk reductions in patients with a more recent heart failure hospitalization. …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …

… transporter 2 inhibition with dapagliflozin, in addition to … heart failure to a greater extent
in patients with heart failure with reduced ejection fraction than in those without heart failure …

… Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the primary composite
outcome of cardiovascular death or worsening heart failure (HF) in patients … of dapagliflozin …

… In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …

… In patients with heart failure and reduced ejection fraction, use of … These beneficial effects
of dapagliflozin in heart failure with reduced ejection fraction may potentially extend to patients …